Free Trial
→ Trump just signed it (From Investors Alley) (Ad)tc pixel Free TAK Stock Alerts

Takeda Pharmaceutical (TAK) Stock Forecast & Price Target

Takeda Pharmaceutical logo
$15.96 -0.19 (-1.15%)
Closing price 05/29/2026 03:59 PM Eastern
Extended Trading
$15.98 +0.01 (+0.06%)
As of 05/29/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

Takeda Pharmaceutical - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy
Based on 4 Analyst Ratings
Sell
0
Hold
2
Buy
2

Based on 4 Wall Street analysts who have issued ratings for Takeda Pharmaceutical in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 4 analysts, 2 have given a hold rating, and 2 have given a buy rating for TAK.

Consensus Price Target

N/A

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for TAK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Takeda Pharmaceutical and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TAK Analyst Ratings Over Time

TypeCurrent Forecast
5/30/25 to 5/30/26		1 Month Ago
4/30/25 to 4/30/26		3 Months Ago
3/1/25 to 3/1/26		1 Year Ago
5/30/24 to 5/30/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price TargetN/AN/AN/AN/A
Forecasted UpsideN/AN/AN/AN/A
Consensus RatingModerate BuyModerate BuyHoldBuy

TAK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TAK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Takeda Pharmaceutical Stock vs. The Competition

TypeTakeda PharmaceuticalMedical CompaniesBroader Market
Consensus Rating Score
2.50
2.30
2.52
Consensus RatingModerate BuyHoldModerate Buy
Predicted UpsideN/A1,738.70% Upside14.83% Upside
News Sentiment Rating
Neutral News

See Recent TAK News
Positive News
Positive News
Export
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
4/29/2026
Weiss Ratings logo
Weiss Ratings
Not Rated
 Reiterated RatingHold (C)
4/8/2026
Sanford C. Bernstein logo
Sanford C. Bernstein
4 of 5 stars
 UpgradeMarket Perform ➝ Outperform
3/3/2026
Zacks Research logo
Zacks Research
Not Rated
 UpgradeStrong Sell ➝ Hold
1/13/2026
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Initiated CoverageOverweight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 04:20 PM ET.


Should I Buy Takeda Pharmaceutical Stock? TAK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, May 26, 2026. Please send any questions or comments about these Takeda Pharmaceutical pros and cons to contact@marketbeat.com.

Takeda Pharmaceutical
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Takeda Pharmaceutical Company Limited:

  • Takeda Pharmaceutical Company Limited is expected to launch several new products, including TAK-881, which has the potential to significantly improve treatment for primary immunodeficiency disease by delivering required doses in a smaller volume.
  • The company is undergoing a transformation program aimed at enhancing operational efficiency, with projected annualized gross savings exceeding JPY 200 billion by fiscal 2028, which could positively impact profitability.
  • The current stock price is around $16.74, reflecting a stable position within the market, with a twelve-month high of $18.90, indicating potential for growth.
  • Takeda's strategic focus on advancing late-stage assets and maintaining resilience in core brands positions it well for future growth, particularly in the biopharmaceutical sector.
  • Institutional investors have shown increased interest, with several hedge funds boosting their positions, suggesting confidence in the company's future performance.

Takeda Pharmaceutical
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Takeda Pharmaceutical Company Limited for these reasons:

  • The company is facing significant restructuring costs of JPY 170 billion this year, which could impact short-term financial performance and investor sentiment.
  • Takeda has not provided growth projections beyond fiscal 2026, which may create uncertainty for investors regarding long-term profitability and market positioning.
  • The company’s debt-to-equity ratio stands at 0.56, indicating a moderate level of debt that could pose risks if not managed effectively, especially in a fluctuating market.
  • With a PE ratio of 69.84, the stock may be considered overvalued compared to industry peers, which could deter value-focused investors.
  • Recent changes in board leadership may lead to shifts in strategic direction, introducing potential volatility as the company adapts to new governance.

TAK Forecast - Frequently Asked Questions

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TAK shares.

According to analysts, Takeda Pharmaceutical's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.

Over the previous 90 days, Takeda Pharmaceutical's stock had 2 upgrades by analysts.

Takeda Pharmaceutical has been rated by research analysts at Sanford C. Bernstein, Weiss Ratings, and Zacks Research in the past 90 days.

Analysts like Takeda Pharmaceutical more than other "medical" companies. The consensus rating for Takeda Pharmaceutical is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how TAK compares to other companies.

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Takeda Pharmaceutical Recommendations


This page (NYSE:TAK) was last updated on 5/30/2026 by MarketBeat.com Staff.
From Our Partners
One hidden supplier shipped 5 billion parts to SpaceX
Most investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...
Weiss Ratings | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
I paid $5,000 to hear Elon say this
One investor paid $5,000 to be in a private room with Elon Musk in Los Angeles - and what he heard confirmed a...
InvestorPlace | Sponsoredtc pixel
How to claim a stake in SpaceX before the June 12 IPO
SpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...
Brownstone Research | Sponsoredtc pixel
Trump Is Eyeing the Biggest Monetary Shift Since Nixon
On August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...
Americas Gold Company | Sponsoredtc pixel
When SpaceX goes public your retirement pays the price
When SpaceX files its S-1, institutions will liquidate holdings, rebalance portfolios, and free up capital for...
Reagan Gold Group | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel